Development of Autoimmune Hepatitis during Direct-acting Antiviral Therapy for Chronic Hepatitis C Virus Infection

Kotaro Matsumoto, Kentaro Kikuchi, Yusuke Kajiyama, Yuichi Takano, Masatoshi Mabuchi, Shinpei Doi, Koichiro Sato, Hiroshi Miyakawa, Ichiro Yasuda

Internal Medicine · 2018 · 19 citations · 20 references

DOIFull text

Open access

Concepts

Abstract

An 81-year-old woman developed liver dysfunction after two months' treatment with direct-acting antivirals (DAAs) for chronic hepatitis C virus (HCV) infection. She was positive for serum anti-nuclear antibody, with an elevated immunoglobulin G level. A liver biopsy revealed high-grade interface hepatitis and infiltrate of lymphocytes and plasma cells. DAA-associated drug-induced autoimmune hepatitis (DI-AIH) was considered. Her liver dysfunction improved after discontinuing DAA therapy and starting prednisolone treatment. The differential diagnosis for AIH should include liver injury during DAA therapy for chronic HCV infection.

References

20